August 03, 2016 12:14pm EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NASDAQ:OPK) will release operating and
financial results for the three and six months ended June 30, 2016,
after the close of the U.S. financial markets on Monday, August 8, 2016.
OPKO’s senior management will provide a business update and discuss its
results in greater detail in a conference call and live audio webcast at
4:30 p.m. Eastern time on Monday, August 8, 2016.
The conference call dial-in information is listed below. To access the
webcast, please log on to the OPKO website at www.opko.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required.
CONFERENCE CALL & WEBCAST INFORMATION
WHEN: Monday, August 8, 2016, 4:30 p.m. ET
DOMESTIC DIAL-IN: (866)
INTERNATIONAL DIAL-IN: (330) 863-3454
For those unable to participate in the conference call or webcast, a
replay will be available beginning August 8, 2016 at 7:30 p.m. ET for a
period of time. To access the replay, dial (855) 859-2056 or (404)
537-3406. The replay passcode is: 56394307.
The replay can also be accessed for a period of time on OPKO’s website
at www.opko.com .
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry leading positions in large, rapidly growing markets.
Our diagnostics business includes Bio-Reference Laboratories, the
nation’s third largest clinical laboratory with a core genetic testing
business and a 420-person sales force to drive growth and leverage new
products, including the 4Kscore ® prostate cancer test and the
Claros ® 1 in-office immunoassay platform. Our pharmaceutical
business features RAYALDEE, an FDA approved treatment for SHPT in stage
3-4 CKD patients with vitamin D insufficiency, and VARUBI™ for
chemotherapy induced nausea and vomiting (oral formulation launched by
partner Tesaro and IV formulation PDUFA date: January 2017). Our
biologics business includes hGH-CTP, a once weekly human growth hormone
injection (in Phase 3 and partnered with Pfizer), and a long acting
Factor VIIa drug for hemophilia (Phase 2a). We also have production and
distribution assets worldwide, multiple strategic investments and an
active business development strategy. More information is available at www.opko.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160803006232/en/
Tara Mackay, 305-575-4100
Investor
Relations
or
Rooney & Associates
Terry
Rooney, 212-223-0689
or
Marion
Janic, 212-223-4017
or
LHA
Anne
Marie Fields, 212-838-3777
or
Bruce
Voss, 310-691-7100
Source: OPKO Health, Inc.
Released August 3, 2016
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page